Alan H. Horwich
#131,290
Most Influential Person Now
Alan H. Horwich's AcademicInfluence.com Rankings
Alan H. Horwichphilosophy Degrees
Philosophy
#6386
World Rank
#9416
Historical Rank
Logic
#3560
World Rank
#4742
Historical Rank

Download Badge
Philosophy
Alan H. Horwich's Degrees
- Doctorate Medicine Harvard University
Why Is Alan H. Horwich Influential?
(Suggest an Edit or Addition)Alan H. Horwich's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers (1997) (1180)
- Carboplatin/cisplatin (1988) (1123)
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (1023)
- Multiple newly identified loci associated with prostate cancer susceptibility (2008) (866)
- Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial (1999) (761)
- Testicular germ-cell cancer (2006) (608)
- European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. (2008) (556)
- Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array (2012) (550)
- Guidelines on Testicular Cancer: 2015 Update. (2015) (525)
- Cardiovascular disease as a long-term complication of treatment for testicular cancer. (2003) (517)
- European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). (2004) (476)
- Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. (2000) (453)
- Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. (2007) (435)
- Guidelines on testicular cancer. (2005) (428)
- Identification of seven new prostate cancer susceptibility loci through a genome-wide association study (2009) (428)
- Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. (2005) (420)
- Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. (2002) (398)
- Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. (1992) (389)
- Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015) (381)
- Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. (1999) (363)
- EAU guidelines on testicular cancer: 2011 update. (2011) (344)
- Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. (1997) (326)
- Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. (2003) (324)
- Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. (2010) (316)
- Multiple loci on 8q24 associated with prostate cancer susceptibility (2009) (316)
- Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. (1996) (313)
- Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. (2012) (300)
- Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study (2011) (295)
- Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. (1999) (287)
- Craniopharyngioma--a long-term results following limited surgery and radiotherapy. (1993) (281)
- Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. (2008) (270)
- The dose-rate effect in human tumour cells. (1987) (269)
- Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer (2012) (268)
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019) (266)
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (263)
- Prognostic Factors for Relapse in Stage I Seminoma Managed by Surveillance: A Pooled Analysis (2002) (261)
- Fertility after chemotherapy for testicular germ cell cancers. (1997) (261)
- Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). (2005) (256)
- The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). (1983) (250)
- A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. (2005) (243)
- Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) (241)
- Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. (2001) (240)
- Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects (2005) (233)
- Medium-term outcomes of active surveillance for localised prostate cancer. (2013) (231)
- Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. (2008) (231)
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (221)
- Fertility, gonadal and sexual function in survivors of testicular cancer (2005) (211)
- ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up (2018) (205)
- Surveillance following orchidectomy for stage I testicular seminoma. (1992) (196)
- European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. (2008) (191)
- Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. (2011) (175)
- Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. (1986) (174)
- Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. (2009) (167)
- The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. (1992) (164)
- Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. (2000) (162)
- Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. (2001) (151)
- Testicular germ cell tumours (2013) (151)
- Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. (1998) (150)
- Prostate cancer: ESMO Consensus Conference Guidelines 2012. (2013) (144)
- Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours (1999) (142)
- Long‐term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer (2010) (135)
- Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). (1985) (135)
- Preliminary results of a phase I dose escalation clinical trial using focused ultrasound in the treatment of localised tumours. (1999) (133)
- Metastatic nonseminomatous germ cell tumors of the testis (2002) (133)
- A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. (2013) (131)
- Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. (2012) (131)
- Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. (2001) (128)
- Managing testicular cancer (2001) (124)
- Radiotherapy for stage I seminoma testis: results of treatment and complications. (1986) (121)
- Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (120)
- Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. (2008) (116)
- Early outcomes of active surveillance for localized prostate cancer (2005) (112)
- Optic gliomas: radiation therapy and prognosis. (1985) (110)
- The Biological Basis of Radiotherapy (1989) (109)
- Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials (2004) (109)
- EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. (2019) (108)
- Treatment results and prognostic factors in 101 men treated for squamous carcinoma of the penis. (1997) (107)
- Evaluation of adjuvant psychological therapy in patients with testicular cancer: randomised controlled trial (1998) (106)
- PROGNOSTIC FACTORS IN ADVANCED NON-SEMINOMATOUS GERM-CELL TESTICULAR TUMOURS: RESULTS OF A MULTICENTRE STUDY Report from the Medical Research Council Working Party on Testicular Tumours (1985) (106)
- Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. (1991) (104)
- Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. (1993) (104)
- Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. (2002) (104)
- Orchidectomy alone for stage I seminoma of the testis (1990) (102)
- Management of primary cerebral lymphoma with initial chemotherapy: preliminary results and comparison with patients treated with radiotherapy alone. (1990) (99)
- Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. (2007) (99)
- Treatment of nondysgerminomatous ovarian germ cell tumors (1999) (98)
- Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (96)
- Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. (2001) (95)
- 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. (2012) (95)
- Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. (1989) (94)
- Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report. (1988) (92)
- A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma (2000) (91)
- Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital. (1997) (89)
- Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse (2008) (88)
- A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact (2011) (86)
- Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. (2001) (86)
- Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance. (1991) (86)
- Technological advances in radiotherapy for the treatment of localised prostate cancer. (2005) (83)
- Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. (1991) (82)
- Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. (2009) (81)
- Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma. (1995) (81)
- Late recurrence in 1263 men with testicular germ cell tumors (2002) (81)
- Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. (2006) (81)
- Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma (2013) (81)
- The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. (2007) (79)
- Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. (1997) (79)
- Adaptive-predictive organ localization using cone-beam computed tomography for improved accuracy in external beam radiotherapy for bladder cancer. (2011) (79)
- Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours. (1989) (78)
- Mortality and incidence of second cancers following treatment for testicular cancer (2007) (78)
- Molecular cytogenetic analysis of adult testicular germ cell tumours and identification of regions of consensus copy number change. (1998) (78)
- Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2009) (77)
- Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. (1994) (76)
- Prostate‐specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time (2009) (75)
- Efficacy of low‐dose dexamethasone in castration‐refractory prostate cancer (2007) (74)
- Penile cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013) (73)
- Orchiectomy alone for Stage I testicular non-seminoma. A progress report on the Royal Marsden Hospital study. (1983) (72)
- 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. (2012) (72)
- Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy? (2003) (70)
- A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. (2005) (69)
- Clinical implementation of adaptive hypofractionated bladder radiotherapy for improvement in normal tissue irradiation. (2013) (66)
- 'JEB'--a carboplatin based regimen for malignant germ cell tumours in children. (1990) (65)
- Residual mass following chemotherapy of seminoma. (1997) (64)
- The late effects of cis-platinum on renal function. (1989) (62)
- Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone. (1997) (60)
- Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (60)
- Predictors of histological disease progression in untreated, localized prostate cancer. (2007) (60)
- Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment outcomes from a 30-year experience. (2010) (59)
- Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis. (1987) (59)
- Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. (2015) (57)
- Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. (2003) (56)
- Whole‐body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer (2009) (55)
- Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. (1997) (55)
- Programmed cell death in response to chemotherapeutic agents in human germ cell tumour lines. (1995) (55)
- Surveillance after orchiectomy for stage I seminoma of the testis. (1987) (54)
- Non-Hodgkin's lymphoma presenting with extradural spinal cord compression: functional outcome and survival. (1991) (54)
- High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone (2002) (53)
- Mortality and cancer incidence following radiotherapy for seminoma of the testis. (1994) (52)
- A pilot study of intermittent androgen deprivation in advanced prostate cancer. (1998) (51)
- The activity of single-agent carboplatin in advanced seminoma. (1992) (51)
- Second primary breast cancer after Hodgkin's disease (2004) (50)
- Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma (2005) (50)
- EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. (2019) (49)
- A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitiser RSU-1069. (1986) (48)
- Assessing intra-fractional bladder motion using cine-MRI as initial methodology for Predictive Organ Localization (POLO) in radiotherapy for bladder cancer. (2007) (47)
- EAU Guidelines on testicular cancer, 2011 update (2012) (47)
- Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. (1995) (47)
- Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (47)
- "Bad risk" non-Hodgkin lymphomas. (1983) (47)
- Microsatellite instability in human testicular germ cell tumours. (1995) (45)
- The utility of lactate dehydrogenase in the follow‐up of testicular germ cell tumours (2007) (45)
- Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment (2017) (45)
- Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. (2010) (45)
- The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer (2010) (45)
- Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance (2009) (44)
- Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer. (2016) (44)
- Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis. (1986) (44)
- Hypofractionated radiotherapy for patients with carcinoma of the bladder. (1999) (44)
- The effects of single dose oral hydralazine on blood flow through human lung tumours. (1990) (43)
- Management of the contralateral testis in patients with testicular germ cell cancer. (1990) (42)
- A feasibility study of using gold seeds as fiducial markers for bladder localization during radical radiotherapy. (2007) (42)
- Surveillance in stage I seminoma patients: a long-term assessment. (2010) (42)
- Testicular cancer : investigation and management (1991) (42)
- Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer (2006) (42)
- Salvage radiotherapy in recurrent Hodgkin's disease. (1992) (42)
- The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. (1992) (42)
- Postchemotherapy Residual Masses in Germ Cell Tumor Patients. Content, Clinical Features, and Prognosis (1999) (41)
- Efficacy of palliative low-dose involved-field radiation therapy in advanced lymphoma: a phase II study. (2008) (41)
- Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer. (2001) (41)
- Imaging metastatic testicular germ cell tumours with18FDG positron emission tomography: prospects for detection and management (1995) (39)
- Extragonadal germ cell tumors: relation to testicular neoplasia and management options (2003) (39)
- The role of 18F-FDG PET/CT in the management of testicular cancers (2015) (39)
- Conformal radiotherapy of the pelvis: assessment of acute toxicity. (1993) (39)
- [EAU guidelines on testicular cancer: 2011 update. European Association of Urology]. (2012) (39)
- Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. (1995) (39)
- Detection of occult spinal cord compression with magnetic resonance imaging of the spine. (2007) (39)
- Placental alkaline phosphatase as a tumour marker in seminoma using the H17 E2 monoclonal antibody assay. (1985) (39)
- Primary malignant mediastinal germ cell tumours: improved prognosis with platinum-based chemotherapy and surgery. (1993) (39)
- Thoracic metastasectomy for germ cell tumours: long term survival and prognostic factors. (1998) (39)
- Persistent carcinoma in situ of the testis after chemotherapy for advanced testicular germ cell tumours. (1990) (38)
- Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer (1999) (38)
- cis-Diammine-1, 1-cyclobutane dicarboxylate platinum II (carboplatin) in the treatment of testicular germ-cell tumours: a preliminary report. (1985) (37)
- Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy (2006) (37)
- An analysis of prognostic factors in early stage Hodgkin's disease. (1986) (37)
- The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer (2000) (37)
- Inguinal and iliac lymph node involvement in germ cell tumours of the testis: implications for radiological investigation and for therapy. (1991) (36)
- The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors (2000) (36)
- Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948) (2005) (35)
- Prostate cancer segregation analyses using 4390 families from UK and Australian population‐based studies (2009) (34)
- Influence of delay in diagnosis on prognosis in testicular teratoma. (1989) (34)
- Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors (2013) (34)
- Clinical presentation as a predictor of laparotomy findings in supradiaphragmatic stage I and II Hodgkin's disease. (1986) (34)
- Etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with small-volume metastases of testicular nonseminoma. (1985) (33)
- Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma. (2013) (32)
- Germ cell tumour chemotherapy. (1989) (32)
- Circulating lymphoma cells in patients with B & T non-Hodgkin's lymphoma detected by immunoglobulin and T-cell receptor gene rearrangement. (1987) (31)
- Bulky mediastinal Hodgkin's disease management and prognosis (1984) (31)
- Technetium-99m HMPAO and SPECT in the assessment of blood flow in human lung tumours. (1989) (30)
- Diethylstilbestrol in castration‐resistant prostate cancer (2012) (30)
- Serum tumour marker regression rate following chemotherapy for malignant teratoma. (1984) (30)
- Risk of premature menopause after treatment for Hodgkin's lymphoma. (2014) (29)
- Tumours of the prostate. (2001) (28)
- Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation. (2010) (28)
- The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. (2012) (28)
- Patterns of care in the management of seminoma stage I: results from a European survey (2012) (27)
- Oncology : a multidisciplinary textbook (1995) (27)
- Risk factors for carcinoma in situ of the contralateral testis in patients with testicular cancer. An interim report. (1993) (27)
- Markers and management of germ-cell tumours of the testes (1998) (27)
- A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone (2006) (27)
- The association of germ cell tumours of the testis with sarcoid-like processes. (1992) (27)
- Cost versus benefit in non-surgical management of patients with cancer. (1988) (27)
- Prospective study of factors predicting adherence to medical advice in men with testicular cancer. (2009) (26)
- Second malignancies and Hodgkin's disease--the Royal Marsden Hospital experience. (1988) (26)
- Ejaculatory dysfunction after retroperitoneal lymphadenectomy. (1993) (26)
- Accelerated chemotherapy for poor prognosis germ cell tumours. (1994) (25)
- Evaluating inter-fractional changes in volume and position during bladder radiotherapy and the effect of volume limitation as a method of reducing the internal margin of the planning target volume. (2008) (24)
- Treating IIA/B seminoma with combination carboplatin and radiotherapy. (2009) (24)
- Does magnetic resonance imaging of the spine have a role in the staging of prostate cancer? (2009) (24)
- Radiotherapy in stage I seminoma of the testis. (2004) (24)
- Prognostic factors for survival in advanced non-seminomatous germ cell tumours: A study by the Medical Research Council Testicular Tumours Working Party (1990) (24)
- The management of advanced testicular teratoma. (1988) (24)
- DOXORUBICIN, RADIOTHERAPY, AND ŒSOPHAGEAL STRICTURE (1975) (24)
- Clinical and technical aspects of conformal therapy (1993) (24)
- Prognosis of testicular teratoma differentiated. (1994) (23)
- Identification of new genetic risk factors for prostate cancer. (2009) (23)
- EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. (2019) (23)
- The management of paratesticular rhabdomyosarcoma. (1989) (22)
- Abdominal relapse in stage 1 nonseminomatous germ cell tumours of the testis managed by surveillance or with adjuvant chemotherapy (2000) (22)
- Salvage of relapse of patients with Hodgkin's disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone. A report from the international database on Hodgkin's disease. (1994) (22)
- Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up (2013) (22)
- Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2009) (22)
- The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time--II. Prognostic significance in patients treated by chemotherapy. (1990) (21)
- Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment. (1997) (21)
- Evaluating the effect of reducing the high-dose volume on the toxicity of radiotherapy in the treatment of bladder cancer. (2006) (21)
- Salvage therapy of germ cell tumours. (1995) (21)
- Frequency of screening magnetic resonance imaging to detect occult spinal cord compromise and to prevent neurological deficit in metastatic castration-resistant prostate cancer. (2010) (20)
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2016) (20)
- Prognostic factors in metastatic germ cell tumors. (1990) (20)
- Primary Adult Renal Ewing's Sarcoma: A Rare Entity (2009) (20)
- Tumour staging using magnetic resonance imaging in clinically localised prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy. (2005) (20)
- Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer (2002) (20)
- Molecular Cytogenetic Analysis of Adult Testicular Germ Cell Tumours and Identification of Regions of Consensus Copy Number Change (1998) (19)
- Evaluation by magnetic resonance imaging of the inferior vena cava in patients with non-seminomatous germ cell tumours of the testis metastatic to the retroperitoneum. (1997) (19)
- Carboplatin dose in combination chemotherapy for testicular cancer. (1991) (19)
- Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013 (2017) (19)
- Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma (2004) (18)
- Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder (2015) (17)
- Chemotherapy and radiotherapy for advanced testicular nonseminoma (1983) (17)
- Prostate‐specific antigen velocity in untreated, localized prostate cancer (2007) (17)
- Challenges in treating patients with Down's syndrome and testicular cancer with chemotherapy and radiotherapy: The Royal Marsden experience. (2007) (17)
- Pentoxifylline to treat radiation proctitis: a small and inconclusive randomised trial. (2008) (17)
- Spermatocytic seminoma in a maldescended testis. (1993) (17)
- Sarcoid-like lymphadenopathy in malignant teratoma. (1983) (16)
- Distribution of lymph nodes in men with prostatic adenocarcinoma and lymphadenopathy at presentation: a retrospective radiological review and implications for prostate and pelvis radiotherapy. (2006) (16)
- Combined single course carboplatin with radiotherapy in treatment of stage IIA,B seminoma--a preliminary report. (1994) (16)
- Initial chemotherapy for stage II testicular non-seminoma (2004) (16)
- Systemic treatment for prostate cancer. (2006) (16)
- Use of carboplatin in germ cell tumors of the testis. (1992) (15)
- Conformal radiotherapy at the Royal Marsden Hospital (UK). (1994) (15)
- The management of early‐stage aggressive non‐Hodgkin's lymphoma (1988) (15)
- Stage III Hodgkin's disease--long-term results following chemotherapy, radiotherapy and combined modality therapy. (1989) (15)
- Intracardiac metastases from germ cell tumours--an unusual but important site of metastasis. (1992) (15)
- The effect of carboplatin on renal function in patients with metastatic germ cell tumours. (1991) (15)
- Prostate cancer management. (2004) (15)
- Radiotherapy results in laparotomy-staged Hodgkin's disease. (1988) (15)
- The growth rate of metastatic non-seminomatous germ cell testicular tumours measured by marker production doubling time--I. Theoretical basis and practical application. (1990) (14)
- Does extragonadal presentation impart a worse prognosis to abdominal germ-cell tumours? (1992) (14)
- Changing patterns of relapse in Hodgkin's disease. (1989) (13)
- Randomised Comparison of the Stanford V (SV) Regimen and ABVD in the Treatment of Advanced Hodgkin Lymphoma (HL): Results from a UK NCRI Lymphoma Group Study, ISRCTN 64141244 (2008) (13)
- Questions in the management of seminoma. (1990) (13)
- Severe lung toxicity with a weekly low dose chemotherapy regimen in patients with non‐Hodgkin's lymphoma (1988) (13)
- Outcome of early detection and radiotherapy for occult spinal cord compression. (2007) (13)
- Update on management of seminoma (2010) (13)
- Case report: Malignant teratoma presenting with an adrenal mass (1987) (13)
- Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL) (2007) (12)
- Bleomycin and scuba diving: where is the harm? (2007) (12)
- Embryonal rhabdomyosarcoma arising in a germ cell tumour. (1994) (12)
- Primary chemotherapy after orchidectomy for stage I and II nonseminoma. (1998) (12)
- Treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin. (1987) (12)
- Chemotherapy and radiotherapy for advanced testicular non-seminoma. I. The influence of sequence and timing of drugs and radiation on the appearance of normal tissue damage. (1983) (12)
- Optimal field size in adjuvant radiotherapy (XRT) of stage I seminoma - a randomised trial (1996) (12)
- Increasing the dose intensity of chemotherapy in poor-prognosis metastatic non-seminoma. (1993) (12)
- Current opinion on adjuvant and salvage treatment after radical prostatectomy. (2004) (12)
- Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder (2016) (12)
- Combined radiotherapy and chemotherapy in clinical oncology (1992) (11)
- Seminal analysis after orchiectomy in stage I teratoma. (1988) (11)
- The effect of antiemetics and reduced radiation fields on acute gastrointestinal morbidity of adjuvant radiotherapy in stage I seminoma of the testis: a randomized pilot study. (1997) (11)
- The role of hemoglobin concentration in clinically localized prostate cancer treated with radical radiotherapy +/- neoadjuvant androgen deprivation. (2004) (11)
- Familial predisposition to both male and female germ cell tumours? (1996) (11)
- Treatment of seminoma. (1992) (11)
- Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R‐GEM‐P) is an effective regimen in relapsed diffuse large B‐cell lymphoma (2015) (11)
- Serum micronutrient and antioxidant levels at baseline and the natural history of men with localised prostate cancer on active surveillance (2010) (11)
- Infradiaphragmatic Hodgkin's disease. (1992) (10)
- Prognosis following chemotherapy for metastatic malignant teratoma. (1987) (10)
- GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma (2014) (10)
- Surveillance after orchidectomy for clinical stage I germ-cell tumours of the testis. (1988) (10)
- An analysis of surveillance for stage I combined teratoma--seminoma of the testis. (1996) (10)
- Spermatocytic seminoma: a clinicopathological review of ten patients. (1996) (10)
- Treatment of Cancer, 3rd edn (1997) (9)
- Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy. (2010) (9)
- Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array (2016) (9)
- Brief Report: Phase II Multicenter Study of Temozolomide in Patients with Cisplatin-Resistant Germ Cell Tumors (2011) (9)
- Peripheral blood involvement in non-Hodgkin's lymphoma detected by clonal gene rearrangement as a biological prognostic marker. (1994) (8)
- Haematological toxicity of radiotherapy following high-dose chemotherapy and autologous bone marrow transplantation in patients with recurrent Hodgkin's disease. (1994) (8)
- Hodgkin's Disease of the Epididymis and Testis (1989) (8)
- Current controversies in the management of testicular cancer (1991) (8)
- Long-term follow-up of unresected residual masses following platinum based chemotherapy for metastatic non-seminoma of the testis (MRC Study TE16): a preliminary report (1998) (8)
- Prostate Radiotherapy: Evaluating the Effect of Bladder and Rectal Changes on Prostate Movement - A CT Study (2006) (8)
- Minimizing toxicity in early-stage testicular cancer treatment (2012) (7)
- Prognostic factors in patients (pts) with advanced metastatic seminoma (SEM) treated with either single agent carboplatin (CP) or cisplatin-based (DDP) combination chemotherapy (CTX): a meta-analysis of prospective European trials. (2002) (7)
- The impact of hydronephrosis on renal function in patients treated with cisplatin‐based chemotherapy for metastatic nonseminomatous germ cell tumors (1988) (7)
- Rare Tumors of the Testis and Paratesticular Tissues (2006) (7)
- The biological basis of radiotherapy. Second edition (1989) (6)
- The future of radiotherapy. (1990) (6)
- UROLOGY AND THE TNM CLASSIFICATION (1988) (6)
- Neoadjuvant chemotherapy for invasive bladder cancer (2005) (6)
- Phase I dose-escalated image-guided adaptive bladder radiotherapy study: Results of first dose cohort (68Gy). (2014) (6)
- Clinical implications of introducing a new PSA assay (2008) (6)
- Current issues in the management of clinical stage I testicular teratoma. (1993) (6)
- The Staging and Treatment of Testicular Cancer: Management of Stage I Disease (1989) (6)
- Uptake of technetium-99m hexamethylpropylene amine oxime labelled white cells in lymph nodes involved in non-Hodgkin's lymphoma (1995) (6)
- Baseline urinary phytoestrogen levels and the natural history of untreated, localised prostate cancer in a British population. (2008) (6)
- Cancer Research Campaign review of radiobiology research. (1993) (6)
- A randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs. estramustine alone in patients with hormone escaped progressive metastatic prostate cancer (1998) (5)
- Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]. (2020) (5)
- Baseline Urinary Phytoestrogen Levels and the Natural History of Untreated, Localised Prostate Cancer in a British Population (2008) (5)
- Breast Cancer after Radiotherapy for Hodgkin's Disease (1998) (5)
- Stage I Seminoma (2006) (5)
- Counselling is not appropriate for all patients with cancer (1999) (5)
- Sites of relapse in seminoma treated with single agent carboplatin chemotherapy: implications for further management. (1992) (5)
- SEMEN CRYOPRESERVATION FOR PATIENTS SURVIVING MALIGNANT DISEASE: IMPLICATIONS OF PROPOSED LEGISLATION (1988) (5)
- Radical radiotherapy for carcinoma of the anal canal. (1990) (5)
- Management of early prostate cancer. (2002) (5)
- Stage I seminoma and carboplatin risks. (2007) (5)
- Populations of Exposure to Low Levels of Ionizing Radiations (Committee on the Biological Effects of Ionizing Radiations (1986) (4)
- Circulating tumor markers. (2008) (4)
- Residual masses post-chemotherapy for germ cell tumour: content, clinical features and prognosis (1998) (4)
- The familial influence on bilateral testicular germ cell cancer: Medical Research Council study TER2. (2006) (4)
- Corrigendum to: "European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer (2008) (4)
- The ESMO guideline strategy: an identity statement and reflections on improvement. (2015) (4)
- 2-18fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residuals: A retrospective validation of the SEMPET trial. (2010) (4)
- Radiotherapy update. (1992) (4)
- The management of early Hodgkin's disease. (1990) (4)
- A randomised trial of 30Gy vs 20Gy in the adjuvant treatment of stage I testicular seminoma (MRC TE18, EORTC 30942, ISRCTN 8525328) (2005) (4)
- A randomized phase II trial of dexamethasone versus prednisolone as secondary hormonal therapy in CRPC. (2013) (4)
- Small-Cell Carcinoma of the Prostate (1997) (4)
- Imaging properties of polydioxanone and titanium ligating clips following para-aortic lymphadenectomy for testicular cancer. (1991) (4)
- Current status of chemotherapy in advanced seminoma. (1997) (4)
- Malignant teratoma presenting with an adrenal mass. (1987) (4)
- Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2007) (3)
- Long-term outcome of high-dose chemotherapy and autologous stem cell transplantation in relapsed/refractory Hodgkin's disease: A cohort of 199 pts from Royal Marsden Hospital. (2006) (3)
- Metastatic non-seminomatous germ cell tumour and dermatomyositis. (1990) (3)
- A phase II multicenter evaluation of ARQ 197 monotherapy in patients with relapsed or refractory germ cell tumors (GCTs). (2011) (3)
- Appendix 9: Testicular seminoma and non-seminoma: eUpdate published online 29 June 2017 (www.esmo.org/Guidelines/Genitourinary-Cancers). (2017) (3)
- Carboplatin-based chemotherapy in good prognosis metastatic non seminoma of the testis (NSGCT): An interim report of an MRC/EORTC randomised trial (1993) (3)
- Management of patients with non-seminomatous germ cell tumours stage I. (1990) (3)
- The role of computed tomography of the brain in the investigation of breast cancer patients with suspected intracranial metastases. (1981) (3)
- Assessment of combination treatment with gemcitabine, cisplatin, and methylprednisolone (Gem-P) in the management of non-Hodgkin T-cell lymphoma. (2010) (2)
- Radiation Resistance and the Dose-Rate Effect: Experimental (1988) (2)
- SECONDARY LEUKAEMIA IN HODGKIN'S DISEASE (1986) (2)
- Minimal benefit from radiotherapy (RT) after chemotherapy (CT) for metastatic seminoma: analysis of Medical Research Council (MRC-UK) database (1997) (2)
- Intensity Modulated Radiotherapy (IMRT) Can Safely Deliver 60 Gy to the Pelvic Lymph Node Regions in Patients with Prostate Cancer: Report of a Phase I Dose Escalation Study (2009) (2)
- Carboplatin (Jm8), Vp16, Bleomycin - (Jeb) in Children with Malignant Germ-Cell Tumors (Mgct) (1987) (2)
- Accelerated chemotherapy for germ cell cancer. (2014) (2)
- Primary chemotherapy: how does it compare with surgery? (1996) (2)
- Chemotherapy of seminoma. (1993) (2)
- Lymphocyte-predominant Hodgkin's lymphoma. (2010) (2)
- Stanford V (SV) Regimen Versus ABVD for the Treatment of Advanced Hodgkin Lymphoma (HL): Results of a UK NCRI/LTO Randomised Phase II Trial. (2004) (2)
- Late CT surveillance in nonseminoma germ cell tumors (NSGCT). (2011) (2)
- Current controversies in the treatment of testicular cancer. (1991) (1)
- Erratum: Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder (British Journal of Cancer (2015) 112, (1626-1635)) doi: 10.1038/bjc.2015.109 (2016) (1)
- Organ preservation of bladder cancer (1993) (1)
- Dose Escalated Adaptive Bladder Radiotherapy: Clinical Outcomes of a Phase I Study (2020) (1)
- Haematological morbidity in patients with Hodgkin's disease treated with radiotherapy following autologous bone marrow transplantation (1993) (1)
- Evaluating the Impact of Volume Limitation as a Method of Reducing the Internal Margin of the PTV in Bladder Radiotherapy (2007) (1)
- Testicular cancer. (1989) (1)
- The incidence of germline p53 mutations in 53 Li-Fraumeni-like families and in individuals with multiple primary tumors (1994) (1)
- Gemcitabine, cisplatin and methylprednisolone (GEM-P) in patients with T-cell lymphoma: Results from The Royal Marsden Hospital. (2006) (1)
- Reply to the letter to the editor 'Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy' by Tannock et al. (2016) (1)
- Can bleomycin toxicity in the treatment of testis cancer be batch related? (2005) (1)
- Technetium-99m HMPAO andSPECTintheassessment ofblood flowinhumanlungtumours (1989) (1)
- Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013 (2014) (1)
- The Role of Surveillance versus Adjuvant Treatment in Stage I Germ Cell Tumors: Outcomes and Challenges. (2015) (1)
- Quantitating risk of contralateral testicular carcinoma in situ (CIS) in patients with testicular cancer an MRC study (1996) (1)
- 497 oral PHASE III PILOT STUDY OF DOSE ESCALATION USING CON-FORMAL RADIOTHERAPY IN PROSTATE CANCER: LONG TERM FOLLOW UP (2011) (1)
- Associated With Primary Mediastinal Nonsemino-matous Germ Cell Tumors (1999) (1)
- Proliferative Fraction in Human Bladder Carcinoma Measured by Ki-67 Antibody Labelling—Its Potential Clinical Use (1989) (1)
- Accelerated chemotherapy in the treatment of urothelial cancer. (2001) (1)
- Multidisciplinary treatment of cancer: radiotherapy (2004) (1)
- Carboplatin in the combination chemotherapy of non-seminomatous germ cell tumours. (1996) (1)
- Book Review Bladder Cancer: Biology, diagnosis, and management Edited by Konstantine N. Syrigos and Donald G. Skinner. 410 pp., illustrated. New York, Oxford University Press, 1999. $129.50. 0-19-263038-5 (2000) (1)
- Presentation of germ cell tumors. (2003) (1)
- Chemotherapy for metastatic seminoma. (2003) (1)
- [Basic principles and initial results of adjuvant hormone therapy and irradiation of prostatic carcinoma]. (1997) (1)
- Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs. estramustine alone in patients with hormone escaped prostate cancer (1999) (1)
- Intensity modulated radiation therapy. (2004) (1)
- Hodgkin's disease of the liver; prognosis and possible indications for radiotherapy. (1991) (1)
- A trial of carboplatin-based combination chemotherapy in good prognosis metastatic NSGCT (1994) (1)
- Proffered paper non-Hodgkin's diseasePeripheral blood involvement in non-Hodgkin's lymphoma (NHL) detected by clonal gene rearrangement as a biological prognostic marker (1993) (1)
- Retroperitoneal lymph-node dissection after chemotherapy for germ cell cancer in patients with elevated tumor markers (2006) (1)
- A trial of accelerated fractionation (AF) in T2/3 bladder cancer (1999) (1)
- Is there a volume effect for acute side-effects following pelvic radiotherapy? (1993) (1)
- Factors Associated with Bleomycin Lung Toxicity in Germ Cell Tumour Patients Treated at the Royal Marsden Hospital Between 1982 and 1999 (2002) (0)
- The prognostic value of PSA derivatives in favourable risk localised prostate cancer (2007) (0)
- Walter & Miller's Textbook of Radiotherapy (5th edn) (1994) (0)
- Intens ive Induct ion Chemotherapy With CBOP / BEP in Pat ients With Poor Prognosis Germ Cel l Tumors (2003) (0)
- Stage II Seminoma and Advanced Disease (2011) (0)
- Prospective phase 1 study assessing feasibility of IMRT and IGART to deliver simultaneous integrated high-dose tumor boost (up to 70 Gy) for the radical treatment of localized muscle-invasive bladder cancer. (2015) (0)
- Serum tumour marker patterns, after chemotherapy for malignant germ-cell tumours, of the testis (1987) (0)
- 132A reanalysis of the royal marsden hospital testicular teratoma surveillance programme (1996) (0)
- Book reviewsIntraoperative Radiation Therapy. Ed. by DobelbowerR. and AbeM., pp. x + 413, 1989 (CRC Press, Florida), £127.50. ISBN 0–8493–6846–4 (1991) (0)
- Rituximab, gemcitabine, cisplatin, and methylprednisolone (R-GEM-P) in treatment of relapsed diffuse large B-cell lymphoma (DLBCL). (2013) (0)
- Radical radiotherapy for T1 bladder cancer: The experience of the royal marsden hospital (1993) (0)
- Time Course of Recovery of Serum Testosterone Following Short Course Neo Adjuvant LHRH Analogue and Radical Radiotherapy in Localised Prostate Cancer (2005) (0)
- TREATMENT OF TESTICULAR TUMOURS (1983) (0)
- 4500 ORAL Evidence based guidelines for the follow-up of testicular cancer (2007) (0)
- Editorial Conservative Treatment of Bladder Cancer (2004) (0)
- The efficacy of preventing neutropenic sepsis in patients with testicular germ cell tumours: results of two consecutive audits. (2010) (0)
- Optimal P lanning T arget V olume f or S tage I T esticular Seminoma: A M edical R esearch C ouncil R andomized T rial (2013) (0)
- A prognostic model for response and outcome in patients with extragonadal germ cell tumors — an international multivariate analysis (2001) (0)
- Management of Testicular Germ Cell Tumors (2003) (0)
- Anthropomorphic and hormone abnormalities in testicular cancer patients. (2011) (0)
- Salvage therapy: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. (2011) (0)
- Management Strategies for Hormone-Refractory Prostate Cancer (2006) (0)
- PO-0680 DOSIMETRIC COMPARISON OF FORWARD PLANNED IMRT (F-IMRT), INVERSE PLANNED IMRT (I-IMRT) AND VMAT FOR PROSTATE CANCER (2012) (0)
- Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (0)
- Radiotherapy and its relationship to radiobiology (1990) (0)
- Corrigendum to: Pentoxifylline to Treat Radiation Proctitis: A Small and Inconclusive Randomised Trial (2008) (0)
- Guidelines EAU Guidelines on Testicular Cancer : 2011 Update (2012) (0)
- EP-1240: Clinical outcomes of image guided adaptive radiotherapy (IGART) for hypofractionated treatment of bladder cancer (2015) (0)
- The role of F-18fluorodeoxyglucose positron emission tomography – computed tomography in the management of testicular cancers. (2015) (0)
- Germ Cell Tumours (2006) (0)
- One Size Doesn't Fit All: The Value of Adaptive Radiotherapy (ART) Planning Methods using Daily Image Guidance in Bladder Radiotherapy (RT) (2008) (0)
- TRENDS AND SOCIO-ECONOMIC INEQUALITIES IN CANCER SURVIVAL OF PATIENTS WITH HODGKIN’S DISEASE DIAG- NOSED IN ENGLAND AND WALES BETWEEN 1986 AND 1999 (2005) (0)
- Diethylstilbestrol (DES) in hormone resistant prostate cancer (HRPC): PSA response, palliative benefit and survival (2001) (0)
- clinical practice guidelines Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2010) (0)
- Prognostic factors in low grade NHL (A multivariate analys) (1997) (0)
- Controversies in testicular cancer management. (1995) (0)
- 9. Hydralazine increases blood flow through human lung tumours (1990) (0)
- 671Bilateral germ cell tumours of the testis (2005) (0)
- 4004 ORAL Avoiding overtreatment of prostate cancer: optimising patient selection for active surveillance (2007) (0)
- No Beyer et al consensus Ann Oncol 2012 (2012) (0)
- Multivariate Analysis of Predictive Factors of Late Relapse in 1264 Patients with Testicular Germ Cell Tumours (2002) (0)
- 4511 POSTER Selective organ preservation in muscle-invasive transitional cell carcinoma of the bladder: Pilot study for a randomised phase III trial (2007) (0)
- Durable Remissions Achieved with R-CHOP Chemotherapy without Radiotherapy in Patients with Primary Mediastinal B-Cell Lymphoma - the Royal Marsden Experience (2018) (0)
- Re: Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. G. J. Fellows et al. Br. J. Urol., 70, 304-309, 1992. (1993) (0)
- 928: Bone Metastases from Testicular Tumours: Management and Outcomes (2004) (0)
- Basic principles of clinical trials as applied to testicular cancer. (1990) (0)
- Management of germ cell tumours of the testis (1999) (0)
- Autologous peripheral blood stem cell rescue permits administration of high activities of rhenium-186 HEDP in progressive hormone refractory prostate cancer metastatic to bone (2002) (0)
- Stage I Testicular Non Seminoma (2011) (0)
- 7183 Outcomes in metastatic (met) germ cell tumours (GCT): 5-year experience from a single institution (2009) (0)
- Identification and Management of High Risk Testicular Germ Cell Tumours: Conclusions, Perspectives and Closing Remarks (1993) (0)
- Reply: Seminoma stage 1: Patterns of care in Europe. (2013) (0)
- Cardiovascular D isease a s a L ong-Term C omplication o f Treatment f or T esticular C ancer (2003) (0)
- Genitourinary cancers (2019) (0)
- Fertility and Quality of Life after Treatment for Testicular Cancer (2002) (0)
- EUROPEAN ASSOCIATION OF UROLOGY (2006) (0)
- Diagnosis and treatment of urological malignancy: the testes. (1996) (0)
- LOW TOXICITY PLATINUM COMBINATION CHEMOTHERAPY (PMO) FOR UROTHELIAL CANCER (1990) (0)
- appendix 8: Prostate cancer: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Genitourinary-Cancers). (2016) (0)
- Reply (2013) (0)
- Seminoma stage 1: Patterns of care in Europe Reply (2013) (0)
- CARBOPLATIN DOSE DETERMINATION USING A SIMPLE FORMULA - SINGLE AGENT, COMBINATION AND HIGH-DOSE STUDIES (1989) (0)
- Surveillance for low-stage testicular germ cell cancers (2006) (0)
- British Association for Cancer Research/Association of Cancer Physicians/British Oncological Association/Joint Symposium on `Radiotherapy - 100 Years On' (incorporating the 1995 Gordon Hamilton-Fairley Memorial Lecture), 'The Tumour and its Environment' and 'Whither High Dose Chemotherapy?' and BACR (1996) (0)
- Chapter 8 The role of bisphosphonates in the systemic treatment of prostate cancer (2010) (0)
- Autologous bone marrow transplantation and radiotherapy in patients with Hodgkin's disease (1993) (0)
- Low Dose Rate in Clinical Radiotherapy (1988) (0)
- Adjuvant treatments for locally advanced prostate cancer. (2011) (0)
- Management strategies for prostate cancer (2006) (0)
- CHAPTER 14 – Germ cell tumors (2009) (0)
- High Dose Chemotherapy with Haemopoietic Stem Cell Support (1994) (0)
- Risk o f S econd M alignancy A fter H odgkin's D isease i n a Collaborative B ritish C ohort: T he R elation t o A ge a t T reatment (2000) (0)
- Intensive I nduction C hemotherapy W ith C BOP/BEP i n P atients With P oor P rognosis G erm C ell T umors (2003) (0)
- GONADOTROPIN AND SEX-HORMONE LEVELS IN TESTIS CANCER-PATIENTS WITH AND WITHOUT CARCINOMA IN-SITU OF THE CONTRALATERAL TESTIS (1994) (0)
- Adjuvant chemotherapy for high-risk low-stage germ-cell tumours (2002) (0)
- Paper429-07 feb 1998 (1998) (0)
- Benefit of radiotherapy dose escalation in localized prostate cancer with respect to expression of intrinsic markers of hypoxia. (2009) (0)
- Haematological malignancies (Chapter 27) (2002) (0)
- The relative risk of secondary tumors in extragonadal germ cell tumors (EGGCT) (1999) (0)
- High activity rhenium-186 HEDP with peripheral blood stem cell support -a novel approach to hormone refractory prostate cancer metastatic to bone (2001) (0)
- 902 Optimal field size in adjuvant treatment of stage I seminoma (1995) (0)
- A report of the 13 cases of primary small cell carcinoma of the urinary bladder: The Royal Marsden Hospital experience. (2001) (0)
- Carboplatin based chemotherapy in the treatment of advanced urothelial cancer with poor prognostic features. (2002) (0)
- Evaluating the Relationship Between Erectile Dysfunction and Dose Received by the Penile Bulb in Patients Undergoing Conformal Radiotherapy for Prostate Cancer: Analysis of Data From the MRC RT01 Dose Escalation Trial (ISRCTN47772397) (2005) (0)
- The Impact of Hydronephrosis on Renal Function in Patients Treated with Cisplatin-Based Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumors (1989) (0)
- The role of radiotherapy in non-Hodgkin's lymphoma. (2004) (0)
- 21. Role of PET imaging with 18F-deoxyglucose (18F-FDG) in the management of testicular germ cell tumours (1994) (0)
- Is apoptosis an important mode of death in embryonal carcinoma (1994) (0)
- 4501 ORAL Long term neurological and peripheral vascular toxicity following chemotherapy treatment of testicular cancer (2007) (0)
- Management of extragonadal seminoma (EG-SEM) — Results of a multicenter analysis of 104 patients (PTS) (1999) (0)
- Conservative treatment of bladder cancer. (2004) (0)
- 236Hypofractionated radiotherapy for primary carcinoma of the bladder in geriatric patients (1996) (0)
- Immunological investigation of lymphoid neoplasms, G. T. Stevenson, J. L. Smith, T. J. Hamblin, Churchill Livingstone, Edinburgh, London, Melbourne and New York, 1983. No. of pages: i–xi + 91 (incl. index). Price: £18.00. ISBN 0 443 02452 9 (1984) (0)
- 23 Stage 1 testicular germ cell cancers (2011) (0)
- Testicular germ cell tumours and contralateral CIS: British Medical Research Council study. (1996) (0)
- Dosimetric comparison of forward planned IMRT (F-IMRT), inverse planned IMRT (I-IMRT) and VMAT for p (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Alan H. Horwich?
Alan H. Horwich is affiliated with the following schools: